【摘要】 目的:比较阿立哌唑与奎硫平治疗女性首发精神分裂症的疗效和安全性。方法:采用随机、双盲、双模拟平行对照的方法,对符合CCMD-3精神分裂症诊断标准的女性首发精神分裂症患者,随机使用阿立哌唑和奎硫平治疗8周。采用阳性症状与阴性症状量表(PANSS)、临床总体印象量表(CGI)评定疗效,采用不良反应量表(TESS)评定不良反应。结果:101例女性首发精神分裂症患者完成了研究,阿立哌唑组50例,奎硫平组51例。治疗8周后,阿立哌唑组痊愈率为38.0%,显效率为66.0%;奎硫平组痊愈率为35.3%,显效率为66.7%。两组疗效在统计学上无显著性差异(P>0.05)。阿立哌唑组总不良反应发生率为33.3%,奎硫平组总不良反应发生率35.2%,两组间比较在统计学上无显著性差异(P>0.05)。阿立哌唑组和奎硫平组均出现较多的不良反应是嗜睡(14.8%vs19.6%)、头昏和昏厥(11.1%vs12.9%),但两组间比较在统计学上无显著性差异(P>0.05)。阿立哌唑组恶心呕吐、头痛的发生率比奎硫平组多(12.9%:1.9%,P<0.05;16.7%vs1.9%,P<0.01),奎硫平组口干、食欲减退或厌食比阿立哌唑组多(均为14.8%vs1.9%,P<0.05)。两组锥体外系反应不明显,较少引起体重增加和月经紊乱,没有发现溢乳现象。结论:阿立哌唑和奎硫平对女性首发精神分裂症疗效相当,不良反应轻,而且不良反应表现有异同。两种药物均为疗效好、安全性高,对体重和月经影响较小、无溢乳的抗精神病药,有利于提高女性精神分裂症患者服药的依从性。更多还原

【Abstract】 Objective:To compare efficacy and safety of Aripiprazole and Quetiapine in the treatment of female first-episode schizophrenia. Methods:The randomized,double blind,double dummy parallel controlled was designed for this study,All the cases were diagnosed as schizophrenia in accordance with the CCMD-3 diagnosis standard and randomized into two groups which were treated with Aripiprazole or Quetiapine for 8 weeks. The Positive and Negative Syndrome Scale (PANSS),Clinical Global Impression (CGI) and Treatment Emergent Side effect Scale (TESS) were used to evaluate efficacy and adverse effects respectively before and at the ends of 2、4、8 weeks treatment.Results:101 adult female first-episode schizophrenia patients were recruited in this study. The remission rates of Aripiprazole was 38.0% and the significant efficacy rate was 66.0% after 8 weeks while that was 35.3% and 66.7% in Quetiapine group. There was no significant difference between the two groups (P>0.05). The incidence rate of adverse effect was 33.3% in Aripiprazole group and that was 35.2% in Quetiapine group,without any significant difference between them (P>0.05). The adverse effect either in Aripiprazole group or in Quetiapine group was drowsiness (14.8%vs19.6%),dizziness and faint (11.1% vs 12.9%). There was no significant difference between the two groups (P>0.05). The rate of nausea and vomiting,headache in Aripiprazole group was higher than that in Quetiapine group(12.9% vs 1.9%,P<0.05 ; 16.7% vs 1.9%,P<0.01),The rate of dry mouth,decrease of appetite or anorexia in Quetiapine group was higher than that in Aripiprazole group(14.8% vs 1.9%,P<0.05 ;14.8% vs 1.9% ,P<0.05). Both drugs showed low extrapyramidal symptoms,less endocrine change,less weight gain and have not found amenorrhea galactorrhea syndrome during treatment.Conclusions:The results suggest that Aripiprazole is as effective as Quetiapine for the treatment of female first-episode schizophrenia and fewer side effects in them ,Although two drugs have different or the same side effects profile,They both are efficacy and safety antipsychotic drugs in treatment of female first-episode schizophrenia. They are beneficial to improve the therapeutic compliance of female first-episode schizophrenia patients.更多还原